Tango Therapeutics (TNGX)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from TNGX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Tango Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $37M | $25M | $37M | $42M | $62M |
| Net income | -$58M | -$108M | -$102M | -$130M | -$102M |
| Free cash flow | -$61M | -$117M | -$120M | -$132M | -$140M |
| EPS (diluted) | -$0.94 | -$1.23 | -$1.08 | -$1.19 | -$0.87 |
| Operating margin | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
Where the revenue comes from
Revenue by products, fiscal 2024. Every breakdown, year by year.
Superinvestors who own TNGX
From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Tom Steyer Farallon Capital Management LLC |
Added | $384M | 1.8% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | $3M | 0.00% | Q2 2026 |
| Ron Baron Baron Capital (BAMCO) |
New position | $468,900 | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by Tango Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when TNGX trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Tango Therapeutics insiders buying the stock?
No open-market insider purchases of TNGX in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Tango Therapeutics?
3 of the superinvestors Investingly tracks hold TNGX in their latest 13F, including Tom Steyer, Cliff Asness, Ron Baron.
Companies like Tango Therapeutics
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 8, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.